S2 nism for heparin-induced thrombocytopenia of the immune type. Newer. more sensitive test systems were developed and applied to studies comparing the new low LMWHs and heparinoids. These studies showed a lower incidence of immunemediated thrombocytopenia with LMWH. The specificity of the antibody for platelet factor 4-heparin complexes led to the development of new tests in the early 1990s. This was soon followed by experiments with antithrombin drugs such as hirudin and argatroban as replacements for heparin in the HIT-HITT syndrome. Shorter courses of heparin therapy and the use of LMWH in place of heparin had become more standard practice in the 1990s. Key Words: Heparin-Low molecular weight heparin-Heparin-induced thrombocytopenia. prevent red thrombi but not the formation of "white clots." Solandt and Best (8) demonstrated the ability of heparin to retard the clumping of platelets and the formation of white clots in extracorporeal circuits in dogs in the early I940s. The tendency for platelets to clump, aggregate, or agglutinate in vitro was variously described in experiments by Copley and Robb (9,10), Fidlar and Jaques (II), and Quick et al. (12, 13) , who observed that heparin affected the platelet count in some animals and some humans in vitro and in vivo. These experiments did not involve prolonged infusion, but they did demonstrate recovery of the platelet counts in vivo in parallel with the duration of the anticoagulant effect. There were no experiments to elicit the mechanism, but it was observed that the thrombocytopenia effect correlated with increasing doses of heparin (10) . A rapidly injected bolus into dogs at a dose of 1,500 Ulkg caused a drop in the platelet count from 341 ,000/fJ.L to 15,OOO/fJ.L in 3.5 minutes with recovery to 115,000/fJ.L at 60 minutes. A 500 Ulkg dose reduced the platelet count by 40-75% (II). In a single human subject (LB Jaques) given heparin at a dose of 40 Ulkg intravenously, the platelet count fell from 255,000/fJ.L to I55,OOO/fJ.L at 7 minutes and recovered to 255.000/fJ.L by 30 minutes. A similar dose given subcutaneously lowered the platelet count from 180.000/fJ.L to 90,000/fJ.L at 2.5 hours, with full recovery at 13 hours. Quick et al. reproduced these findings in some animals but not in two human subjects (13) . S3 STUDIES FROM 1950 -1970 Few investigations of the effect of heparin on platelets were carried out during the 1950s but a very important and widely quoted report in 1958 by Weismann and Tobin called attention to the fact that paradoxical thromboembolism may occur with heparin therapy (14) . This report of 10 cases of arterial embolism, all to the lower extremities, included one with myocardial infarction and another with stroke and mesenteric vessel occlusion. No venous thrombi or pulmonary emboli were observed. In the discussion of this provocative paper, Dr. Geza de Takats, an early investigator of the clinical use of heparin, commented that "the problem could have arisen because many of the patients received their heparin subcutaneously or intramuscularly for a number of days" rather than intravenously, which "of course gives the body time enough to develop anti heparin substances." As it Was learned 20 or so years later, anti heparin substances (i.e., antibodies) do develop in some patients. The number of patients Weismann and Tobin treated to find this many cases of thromboembolism due to heparin is unknown, but a reasonable estimate based on current knowledge would be approximately 1,000. This number would be derived from current prospective studies that report an incidence of thrombosis due to heparin of about I % of patients treated for at least 5 days with intravenous heparin and a smaller percentage of those treated with subcutaneous heparin (15) . There were no subsequent reports of thromboembolism due to heparin until 1964 When Roberts et a!. (16) reported on II patients detected during a 9-year period who had arterial emboli while receiving heparin therapy. These patients all received heparin for more than 10 days by subcutaneous or intramuscular routes. The emboli (?thrombi) were "light in color" and made up of platelets and fibrin when examined microscopically. The patients were 55 to 82 years of age. All patients had multiple emboli. Four of them died.
The authors felt that an "antigen-antibody reaction" might be the mechanism for the thrombosis and that "anti-heparin factors or platelet agglutinates may be in-Volved." Thus by 1964, 21 patients with heparin-induced thromboembolism had been reported. Platelet counts Were not reported. In 1968 Davey and Lander (17) reported a study of three patients who were given single injections of 10,000 units of radiolabelled heparin who did not develop thrombocytopenia. These investigators Were not convinced that heparin causes thrombocytopenia in humans.
Gollub reported in 1964 .that heparin clearly caused an acute reversible thrombocytopenia in a single human SUbject. The fall in platelet count was maximal when the Lee-White clotting time was maximal and returned to normal when the Lee-White clotting time normalized (J 8).
The introduction of the Coulter counter for automated platelet counting in 1965 made it easier to obtain accurate and timely platelet counts in patients receiving heparin (19) , in spite of the fact that there was no need to monitor platelet counts in patients receiving heparin because there was still controversy as to whether heparin could cause a decrease in platelet counts and whether any adverse event could be attributed to it. A case report by Natelson et a!. in 1969 was possibly the first report of type 2 heparin-induced thrombocytopenia (20) . Not only was it highly probable clinically, but there was also supportive evidence in experimental laboratory testing. The test we now rely on using patient serum, heparin, and control platelet-rich plasma was negative with two donors, but the addition of heparin (5 UlmL) caused aggregation of the patient's own platelet-rich plasma. In a review of reported cases of drug-induced thrombocytopenia, the single case cited here was the only one reported by 1972 (21) .
STUDIES FROM 1970-1990
During the early 1970s and continuing through the 1980s and 1990s, studies of the interaction of platelets with heparin in normal controls in vitro provided muchneeded insight into the reports of heparin-induced platelet aggregation (21, 22) . Evidence that heparin enhanced ADP-induced aggregation as well as platelet adhesion was presented in 1974 (23) . In 1973 Eika showed that modilication of the heparin molecule could influence its ability to aggregate platelets (24) . This included both structural and molecular weight modilication. High molecular weight heparin was shown to aggregate platelets more than lower molecular weight fractions. In 1972, several cases of heparin-induced priapism were reported (25) . The second and third cases of HIT to be reported also had HITT. These well-documented cases were reported by Rhodes et at. in 1973. The authors recognized that the patients who also became heparin resistant were "hypercoagulable." They concluded that antiplatelet drugs and warfarin would be possible treatments for this problem (26) . In 1974 Klein and Bell reported two cases of patients who had disseminated intravascular coagulation while receiving heparin (27) . Another report in 1973 that ultimately proved to be useful in understanding HIT showed that the platelet Fe receptor was a mechanism for antigen-antibody (Ag-Ab) complex-induced platelet injury (28) .
It was not until the mid-1980s that this mechanism was proposed for platelet activation in HIT-HITT (29) . Interesting studies by Zucker in 1974 showed that heparin could induce a release reaction in normal platelets (23) . She also pointed out that the ADP reaction with platelets in vitro is dependent upon a low calcium concentration. Thus, investigators should be careful when describing the in vitro conditions of their experiments (29) . The first prospective study of HIT was reported by Bell et al. in 1976 (30) . That study involved 52 patients receiving conventional heparin therapy for at least 5 days. Platelet counts were performed every other day. All patients received beef lung heparin (The Upjohn Co, Kalamazoo, MI, U.S.A.) infused intravenously. Thrombocytopenia in that study was defined as < 100,000 platelets/ul, on 2 consecutive days. Sixteen of the 52 patients developed thrombocytopenia, including two patients receiving low-dose subcutaneous heparin. Two of the patients experienced bleeding. No thrombotic complications were reported. No laboratory tests to confirm an immune-mediated cause were performed. During 1975 an excellent study of laboratory methods to confirm HIT was carried out by Fratantoni et al. (31) They reported a single case of a patient whose platelets aggregated with heparin in vitro and whose heated (56°C) serum aggregated normal platelets in the presence of heparin, but not in its absence. Tritiated serotonin release from normal platelets using heated patient serum and normal plateletrich plasma also was observed. These investigators could not demonstrate platelet aggregation using the serum of 25 of 27 volunteers. Aggregation in two of the volunteers occurred only with a high concentration of heparin. It was speculated that the platelet aggregation factor in the patient's serum was an antibody (31) . Using these same methods, we at Loyola University Stritch School of Medicine diagnosed two such patients in 1975. By 1981 we had diagnosed more than 100 cases uncovered by performing platelet counts every I to 2 days during heparin therapy (32) . Other reports during the latter part or the 1970s documented many cases of HIT and HITT (33) (34) (35) .
In 1976 Shanberge et al. (35) showed that tritiated heparin was taken up in platelet-rich plasma and in washed platelets as well. Heparin complexed with antithrombin III was not taken up by platelets.
In 1978 Green et al. (36) presented evidence that a serum factor that was heat stable and precipitable with half saturated ammonium sulfate reacted in vitro with radiolabelled heparin bound to normal platelets. This reasonably confirmed the hypothesis that the serum factor was an immunoglobulin. During the 1940s the heparinneutralizing substance in platelets was studied by Conley (37) . Salzman er al. reported on an in-depth study of heparin-platelet interactions in 1980 (38). They reported that platelet aggregation by heparin was impaired by substances that increase cyclic AMP but not by cycloxygenase inhibitors. It did not require ADP (unaffected by apyrase) and did not activate phospholipase C. Ristocetin co-factor was not involved. Antithrombin III bound heparin did not aggregate platelets. Higher molecular weight heparin (20,000 d) aggregated platelets more than low cu« Appl Thrombosis/Hemostasis, Vol. 5. SlIpf,l. I. 199'1 molecular weight heparins. Platelet reactivity was not dependent on anticoagulant activity of the heparin (38).
Studies on the serum revealed that IgG isolated from patient's serum was the active principle that interacted with heparin and platelets to induce aggregation and a release reaction (39, 40) .
Many reports of HIT and HITT appeared during the 1980s. Diagnostic criteria were developed and the syndrome became more widely recognized. Some excellent clinical studies and refinement of laboratory criteria appeared in various journals during the next 10 years, but recommendations for alternative drug use were not supported by prospective clinical studies. It did not become clear until 1982 that a negative clinical laboratory test for HIT did not exclude the diagnosis (41) . Approximately 10-15% of clinical cases had a negative result when tested with the sensitive radioactive serotonin release assay (42) (43) (44) .
It was reported by Capitanio et al. (45) that platelet factor 4 released from alpha granules when platelets were aggregated became bound to the platelet surface by specific sites on the platelet surface.
Reports during the 1980s suggested that LMWH fractions might be useful substitutes for heparin in this syndrome. A number of anecdotal reports supported that concept (46, 47) , but in vitro studies using patient serum from positive HIT cases to which LMWH was added could cause platelet aggregation (48,49). Therefore, it was recommended that LMWH not be used as a substitute for heparin in this syndrome (50). However, it was determined that heparinoids such as dermatan sulfate could be used with reasonable safety provided the drug was negative in the HIT test systems (51). The synthetic pentasaccharide, which contains the binding sequence for antithrombin III did not react with platelets in the HIT test system (52) .
Some analogues of heparin were found to interact with antibodies formed during heparin therapy independent of their molecular weight and anticoagulant activity (53) . Using crossed immunoelectrophoresis methods, Gogstad determined that heparin became bound to glycoprotein Ib (54) . Two other less well defined sites on platelet membranes bound heparin as well. It was reported that dextran 40 could reduce heparin-mediated platelet aggregation in vitro (55). There were suggestions that clinicians might be able to use dextran 40 as a safe substitute for heparin in known HIT cases (56) . No controlled studies have been done to determine the efficacy of dextran 40 in the management of HIT-HITT, although it has been used clinically for this purpose.
Additional therapeutic measures suggested and tried during this period included plasmapheresis to remove the IgG antibody temporarily (57) . Protamine sulfate to remove heparin rapidly from the circulation was advised as well. Antiplatelet drugs were also suggested (58).
It was during this period that bovine lung heparin was eliminated from clinical use in many hospitals because it was reported it was more likely to cause HIT-HITT than was porcine mucosal heparin. In spite of the results of a prospective trial that showed no significant difference in the rates of HIT-HITT when these two drugs were compared (58), there is a persisting belief that bovine lung heparin is more likely to cause the HIT-HITT problem than porcine mucosal heparin.
Clinical and laboratory investigations of HIT-HITT intensified during the 1990s. Clinical studies compared heparin with LMWH given over a period of 5 days or more to determine the incidence of HIT and the associated IgG antibodies. It was shown that HIT-HITT and associated IgG antibodies were more likely to occur with standard heparin. Nine of 332 cases occurred in the heparin group, whereas none occurred in the LMWH group, despite the fact that 2.2% of the LMWH group developed IgG antibodies to heparin as detected in a serotonin release assay (59). In other clinical investigations the safety of substitute drugs to replace heparin in patients with HIT-HITT syndrome was studied. Orgaran (ORG 10172). a heparinoid, was shown to be useful as a substitute drug provided it did not show a reaction in the HIT antibody test (60) . Recombinant hirudin (lepirudin), derived from the salivary gland cells of the blood sucking leech, was very effective as a thrombin inhibitor (61) . Another thrombin inhibitor, argatroban was shown to be an excellent substitute as well (62) . Newer clinical reports began to emphasize that the occurrence of venous exceeded that of arterial thromboembolism in HITT and that massive venous thrombosis could result in gangrene of the leg (63) . Limiting the duration of heparin therapy to 5 days or less, ceasing all heparin injections as soon as the clinical diagnosis of HIT-HITT had been made, and Using LMWH as initial therapy when possible became standard recommendations (64) .
Basic studies of the antibody-antigen reaction resulted in the conclusion that most cases involved an antibody to heparin-platelet factor 4 (PF4) (65.66). Amiral et al. de-Vised an ELISA assay for the heparin PF4 antibody (67) . It proved to be super-sensitive, detecting many patients Who had the antibody, but who did not have thrombocytopenia (68) . Basic studies of the heparin-PF4 complex and its interaction with the antibody and platelets revealed that the antibodies are not always IgG and could be IgA or IgM as well (65) . There were also studies shOWing that certain surface glycoproteins appeared to be involved in the binding of heparin PF4 and the antibody to the platelet surface (69, 73) . Newer antiplatelet drugs became available for use in arterial thrombotic disorders during the I990s. While these drugs have been Shown to block the HIT reaction in vitro. no prospective studies have been reported.
Since understanding of the mechanisms of the platelet destruction and thrombotic complications are necessary for the design of effective and safe prophylactic and therapeutic agents, research in these areas is expected to continue. Heparin still is one of our most valuable drugs in spite of these serious adverse effects. Greater understanding of the clinical and basic immunology involved in HIT-HITT and of the mechanisms by which platelets and endothelium are damaged should permit a more rational approach to this devastating problem.
